FluoroPharma Medical, Inc. (FPMI) CEO Provides Comprehensive Overview of the Company and Future Expectations
FluoroPharma Medical, developer of breakthrough molecular imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of pathology before clinical manifestation of diseases, announced this morning the release of a company overview as presented by FluoroPharma's President, CEO, and Chairman of the Board, Thijs Spoor. The detailed “State of the Union" communication serves to provide shareholders with a perspective on the company, its evolution, and future potential. Mr. Spoor began the communication by stating, "Our company vision is clear, our financial position is sound, our promising product portfolio is on track and our company is led…